Jagsonpal Pharmaceuticals has informed that consequent to the appointment of Pratham Rawal as Company Secretary, the Board of Directors have approved changes in KMPs authorized for the purpose of determining materiality of an event or information and for the purpose of making disclosures to stock exchange(s) under the Listing Regulations. The contact details of the KMPs authorized is enclosed.
The above information is a part of company’s filings submitted to BSE.